SPRINGFIELD, N.J. and WAYNE, Pa., Nov. 4, 2024 /PRNewswire/ — Hudson, a global laboratory automation solutions provider, and Argosy Healthcare Partners portfolio company, announced the appointment of Werner Maas as Chief Executive Officer. Werner is an experienced life science tools industry leader with a proven track record of driving scale, fostering innovation, and leading organizations through transformational growth.
Most recently, Maas served as President of the Global Liquid Handling business of Mettler Toledo, a multinational manufacturer of scales and analytical instruments, where he led the Rainin and Biotix business units. Prior to his tenure with MTD, Maas served as President of the Magnetic Resonance division of Bruker Biospin Group, a life science manufacturer, developer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions.
“Hudson is known for its innovative solutions and deep product portfolio, providing scientists the means to reach higher productivity and reproducible results, and I am excited to join the company at this unique moment in its growth,” said Maas. “I look forward to working with the entire team to build on the company’s strong foundation and help accelerate its success across all markets.”
Dr. Ian Shuttler, Executive Chairman, stated, “We are excited to welcome Werner to Hudson and have him guide the organization through its next stage of growth. Hudson brought together three companies with the acquisitions of Hudson Robotics, Art Robbins Instruments, and Tomtec, and we look forward to Werner uniting the organization and driving customer centricity, innovation, and growth in the years ahead.”
In conjunction with the leadership transition, Andrew Witschi will take on a new role as President of Hudson Robotics and Head of Technology. Hudson Robotics will continue its focus on delivering top-tier automation solutions to its clients, supporting advancements in the life sciences with a commitment to quality, reliability, and cutting-edge innovation.
Hudson
Hudson, formed through the combination of Hudson Robotics, Art Robbins Instruments, and Tomtec, is headquartered in Springfield, New Jersey, and designs, assembles and integrates liquid handling, microplate automation, laboratory robotics, customized software-driven laboratory automation solutions and consumables. Hudson’s instruments are used in drug discovery, clinical research, protein crystallization, high-throughput experimentation and pharmaceutical development. Hudson sells its software, instruments, consumables, and workstations primarily to the pharma, biopharma, academic and OEM end markets.
Argosy Healthcare Partners
Argosy Healthcare Partners (“AHP”) is a lower middle market private equity firm dedicated to healthcare. AHP partners with founder owned healthcare businesses anywhere in the US with $1.0 – $3.0 million of EBITDA and executes majority control transactions. AHP is a platform built for founder-owned companies to support their culture, reinvest in their business, and help accelerate growth.
For further information, please visit:
Hudson: www.hudsonrobotics.com
Argosy Healthcare Partners: www.argosyhp.com
Contact:
Argosy Healthcare Partners
Paul Barrett, Managing Partner
pbarrett@argosyhp.com
Hudson
Werner Maas, CEO
wmaas@hudsonrobotics.com
SOURCE Hudson
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…
BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…
HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…
Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…
Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…